{
Jo Walton

People

}
Very Negative
Negative
Neutral
Positive
Very Positive
2025-03-312025-03-311111100
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-03-312025-03-311111100
Download SVG
Download PNG
Download CSV

ubs maintains buy rating for novo nordisk with target price of 750 crowns

UBS has maintained a "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Recent data indicates a 3.6% increase in first prescriptions for the company's GLP1 weight loss drugs, outpacing competitor Eli Lilly, suggesting steady growth without acceleration.
boerse.de
Danish Krone Novo Nordisk A/S DNK Jo Walton
Finance & Economy, Market Report
14:02 17.02.2025

ubs maintains buy rating for sanofi with target price of 120 euros

UBS has maintained a "Buy" rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton highlighted that the future of Sanofi's immunology products will be influenced by the discussion surrounding copycat drugs for Dupixent expected around 2030, countering skepticism about their medical applications.
boerse.de
Euro Sanofi FRA Jo Walton
Finance & Economy, Market Report
09:58 13.02.2025

ubs maintains buy rating for sanofi with target price of 120 euros

UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton highlighted that the future of Sanofi's immunology products will be influenced by the discussion surrounding copycat drugs for Dupixent expected around 2030, countering skepticism about their medical applications.
MarketScreener
Euro Sanofi FRA Jo Walton
Finance & Economy, Market Report
09:46 13.02.2025

ubs maintains buy rating for novo nordisk with target price of 750 crowns

UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted a 9.4% increase in first prescriptions of the anti-obesity drug Wegovy in the last week of January, with even higher growth observed for the weight loss drug Zepbound.
boerse.de
Danish Krone Novo Nordisk A/S DNK Jo Walton
Finance & Economy, Market Report
15:27 10.02.2025

ubs rates novo nordisk as buy with target price of 750 kroner

UBS has assigned a "buy" rating to Novo Nordisk with a target price of 750 Danish kroner following a company event discussing annual results. Analyst Jo Walton noted management's satisfaction with recent study outcomes for weight loss drugs CagriSema and Amycretin, alleviating prior investor concerns regarding CagriSema's results.
boerse.de
Danish Krone Novo Nordisk A/S DNK Jo Walton
Finance & Economy, Market Report
08:58 07.02.2025

UBS maintains buy rating for Novo Nordisk with target price of 750 crowns

UBS has maintained a 'Buy' rating for Novo Nordisk, setting a target price of 750 Danish crowns. The bank noted that the company's sales and operating profit exceeded market expectations, highlighted during a conference call discussing initial data from the REDEFINE-1 study. Novo Nordisk has seen a remarkable 3,527% increase since its first recommendation by boerse.de.
boerse.de
Danish Krone Novo Nordisk A/S DNK Jo Walton Warren Buffett Thomas Müller Show more
Finance & Economy, Market Report
08:56 06.02.2025

UBS raises GlaxoSmithKline price target while maintaining neutral rating

UBS has increased its price target for GlaxoSmithKline (GSK) from 1580 to 1600 pence while maintaining a "Neutral" rating. Analyst Jo Walton highlighted a strong outlook for GSK in 2025, emphasizing the company's commitment to enhancing shareholder returns.
boerse.de
British Pound Sterling GLAXOSMITHKLINE CAPITAL PLC 4.0 GBR Jo Walton
Finance & Economy, Market Report
08:14 06.02.2025

ubs maintains buy rating for novo nordisk with target price of 750 kroner

UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish kroner. Analyst Jo Walton noted strong growth in first prescriptions of GLP-1 drugs for weight loss, despite a public holiday affecting the previous week's data.
boerse.de
Danish Krone Novo Nordisk A/S DNK Jo Walton
Finance & Economy, Market Report
16:24 03.02.2025

UBS maintains buy rating for Sanofi with target price of 120 euros

UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton expressed optimism regarding the upcoming launches of Dupixent for COPD and Tolebrutinib for smoldering MS following a recent management call.
boerse.de
Euro Sanofi FRA CHE Jo Walton Thomas Müller
Finance & Economy, Market Report
12:48 03.02.2025

ubs maintains buy rating on sanofi with target price of 120 euros

UBS has reaffirmed its "Buy" rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton expressed optimism regarding the upcoming launches of Dupixent for COPD and Tolebrutinib for smoldering MS, following a recent management call. As of February 3, 2025, Sanofi's stock was trading at 104.38 euros, reflecting a slight increase of 0.19%.
aktiencheck.de
Euro Sanofi DEU FRA Jo Walton
Finance & Economy, Market Report
11:48 03.02.2025
Trending
Subcategory
Stock Market Updates Corporate News Industry Trends Global Trade Developments Global Financial Events Banking Regulations Retail and Consumer Goods Startups & Entrepreneurship Central Bank Actions Finance Mergers & Acquisitions Industry Mergers & Acquisitions Inflation and Monetary Impact Government Economic Policies CEO Changes Market Analysis and Predictions Domestic Politics Government Policies Workplace Trends GDP Growth & Recession Forecasts Financial Scams and Security
Countries:
USA CHN GBR CHE IND DEU JPN FRA CAN VNM ARE ESP MEX ITA SGP AUS TWN THA MYS IDN
Companies:
Tesla, Inc. Apple Inc. Barclays PLC JPMorgan Chase & Co. Deutsche Bank Money Market PP The Goldman Sachs Group, Inc. Credit Suisse Strategic Income I Banco Santander, S.A. Berkshire Hathaway Inc. SpaceXCoin USD Bank of America Corporation Morgan Stanley BNP Paribas SA Amazon.com, Inc. UBS Group AG Lloyds Banking Group plc NVIDIA Corporation Bank Frick AG Citigroup Inc. Wells Fargo & Company
Currencies:
United States Dollar Euro British Pound Sterling Japanese Yen Swiss Franc Indian Rupee Chinese Yuan South Korean Won Vietnamese Đồng Canadian Dollar Australian Dollar Thai Baht Indonesian Rupiah Singapore Dollar Mexican Peso New Taiwan Dollar Russian Ruble Hong Kong Dollar Offshore Chinese Yuan New Zealand Dollar
People:
Donald Trump Elon Musk JD Vance Warren Buffett Sergio Ermotti Mark Haefele Jennifer Piepszak Karoline Leavitt Ursula von der Leyen Olivier Calvet Scott Bessent George Saravelos Francois Xavier Bouvignies Joseph Spak Robin Leopold Stefan Rauti Susan P. Crawford Greg Rubini Dan Ives Savio D'souza

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.